Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia (2012)

  • Authors:
  • USP affiliated authors: KRIEGER, JOSE EDUARDO - FM
  • USP Schools: FM
  • DOI: 10.1007/s00228-011-1125-1
  • Subjects: DOR (INDUZIDO QUIMICAMENTE); GENÓTIPOS; HIPERCOLESTEROLEMIA (TERAPIA;EPIDEMIOLOGIA); ANTILIPÊMICOS; BRASIL
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00228-011-1125-1 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s00228-011-1125-1 (Fonte: Unpaywall API)

    Título do periódico: European Journal of Clinical Pharmacology

    ISSN: 0031-6970,1432-1041



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: European Journal of Clinical Pharmacology

    ISSN: 0031-6970

    Citescore - 2017: 2.69

    SJR - 2017: 1.159

    SNIP - 2017: 1.277


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2271693-10BCSEP 015 2012
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SANTOS, Paulo Caleb Junior Lima; GAGLIARDI, Ana Carolina Moron; MINAME, Márcio Hiroshi; et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European Journal of Clinical Pharmacology, Berlin, v. 68, n. 3, p. 273-279, 2012. Disponível em: < http://www.springerlink.com/content/1578304x52786513/fulltext.pdf > DOI: 10.1007/s00228-011-1125-1.
    • APA

      Santos, P. C. J. L., Gagliardi, A. C. M., Miname, M. H., Chacra, A. P., Santos, R. D., Krieger, J. E., & Pereira, A. C. (2012). SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European Journal of Clinical Pharmacology, 68( 3), 273-279. doi:10.1007/s00228-011-1125-1
    • NLM

      Santos PCJL, Gagliardi ACM, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia [Internet]. European Journal of Clinical Pharmacology. 2012 ; 68( 3): 273-279.Available from: http://www.springerlink.com/content/1578304x52786513/fulltext.pdf
    • Vancouver

      Santos PCJL, Gagliardi ACM, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia [Internet]. European Journal of Clinical Pharmacology. 2012 ; 68( 3): 273-279.Available from: http://www.springerlink.com/content/1578304x52786513/fulltext.pdf

    Referências citadas na obra
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278. doi: 10.1016/S0140-6736(05)67394-1
    Ghatak A, Faheem O, Thompson PD (2010) The genetics of statin-induced myopathy. Atherosclerosis 210(2):337–343. doi: 10.1016/j.atherosclerosis.2009.11.033
    Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799. doi: 10.1056/NEJMoa0801936
    Thompson PD, Clarkson PM, Rosenson RS (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97(8A):69C–76C. doi: 10.1016/j.amjcard.2005.12.013
    Armitage J (2007) The safety of statins in clinical practice. Lancet 370(9601):1781–1790. doi: 10.1016/S0140-6736(07)60716-8
    Gotto AM Jr (2006) Statins, cardiovascular disease, and drug safety. Am J Cardiol 97(8A):3C–5C. doi: 10.1016/j.amjcard.2005.12.005
    Law M, Rudnicka AR (2006) Statin safety: a systematic review. Am J Cardiol 97(8A):52C–60C. doi: 10.1016/j.amjcard.2005.12.010
    Nichols GA, Koro CE (2007) Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 29(8):1761–1770. doi: 10.1016/j.clinthera.2007.08.022
    Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR (2011) Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J doi: 10.1038/tpj.2010.92
    Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54(17):1609–1616. doi: 10.1016/j.jacc.2009.04.053
    Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, Konig S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J (2011) Frequency of the SLCO1B1 388A > G and the 521 T > C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method. Eur J Clin Pharmacol doi: 10.1007/s00228-011-1065-9
    Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63(1):157–181. doi: 10.1124/pr.110.002857
    Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82(6):726–733. doi: 10.1038/sj.clpt.6100220
    Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16(12):873–879. doi: 10.1097/01.fpc.0000230416.82349.90
    Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG (2008) The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18(5):424–433. doi: 10.1097/FPC.0b013e3282fb02a3
    Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14(11):749–757
    Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15(7):513–522
    Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I (2006) Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res 23(11):2646–2656. doi: 10.1007/s11095-006-9102-6
    Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA (2008) Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 6(4):567–581. doi: 10.1586/14779072.6.4.567
    Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209(1):189–194. doi: 10.1016/j.atherosclerosis.2009.09.014
    Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN (1993) Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72(2):171–176
    Williams RR, Schumacher MC, Barlow GK, Hunt SC, Ware JL, Pratt M, Latham BD (1993) Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 72(10):18D–24D
    Alvim RO, Freitas SR, Ferreira NE, Santos PC, Cunha RS, Mill JG, Krieger JE, Pereira AC (2010) APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 9:128. doi: 10.1186/1476-511X-9-128
    Santos PC, Cancado RD, Pereira AC, Schettert IT, Soares RA, Pagliusi RA, Hirata RD, Hirata MH, Teixeira AC, Figueiredo MS, Chiattone CS, Krieger JE, Guerra-Shinohara EM (2011) Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis 46(4):302–307. doi: 10.1016/j.bcmd.2011.02.008
    Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, Mill JG, Krieger JE, Pereira AC (2011) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 12:13. doi: 10.1186/1471-2350-12-13
    Puccetti L, Ciani F, Auteri A (2010) Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211 (1): 28–29. doi: 10.1016/j.atherosclerosis.2010.02.026
    Santos PC, Alvim R O, Ferreira NE, de Sa Cunha R, Krieger JE, Mill JG, Pereira AC (2011) Ethnicity and arterial stiffness in Brazil. Am J Hypertens 24(3):278–284. doi: 10.1038/ajh.2010.244